Columnists
Tipsheet
Cartoons
Podcasts
Newsletters
Sections
Podcasts
Townhall TV
Election
Capitol Voices
Entertainment
Radio News
Live Blog
Topics
Sites
Hot Air
PJ Media
Bearing Arms
Twitchy
RedState
JOIN VIP
LOGIN
MY ACCOUNT
Account Settings
Newsletter Subscriptions
Log Out
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Halozyme Therapeutic
(NQ:
HALO
)
50.27
+0.61 (+1.23%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jun 18, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
1,035,344
Open
49.74
Bid (Size)
50.27 (1)
Ask (Size)
51.43 (11)
Prev. Close
49.66
Today's Range
48.99 - 50.84
52wk Range
32.83 - 53.00
Shares Outstanding
142,334,900
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Don't overlook NASDAQ:HALO—it's a hidden gem with strong fundamentals and an attractive price tag.
June 19, 2024
In a market where value is scarce, HALOZYME THERAPEUTICS INC (NASDAQ:HALO) offers a refreshing opportunity with its solid fundamentals.
Via
Chartmill
The 3 Best Healthcare Stocks to Buy in June 2024
June 15, 2024
Aging populations and changing lifestyles mean healthcare is a secular story that these best healthcare stocks to buy will capitalize on.
Via
InvestorPlace
Performance
YTD
+34.45%
+34.45%
1 Month
+11.79%
+11.79%
3 Month
+24.49%
+24.49%
6 Month
+38.18%
+38.18%
1 Year
+45.42%
+45.42%
More News
Read More
Neurocrine Biosciences Stock Tops Milestone Amid New Drug Plans
June 14, 2024
Via
Investor's Business Daily
Madrigal Pharmaceuticals Stock Earns RS Rating Upgrade
June 12, 2024
Via
Investor's Business Daily
Krystal Biotech Stock Sees RS Rating Jump To 91
June 11, 2024
Via
Investor's Business Daily
Novavax And Agios Pharmaceuticals Were Among The 10 Biggest Mid-Cap Gainers Last Week (June 1-June 7): Are These In Your Portfolio?
June 09, 2024
Via
Benzinga
NASDAQ:HALO, a growth stock which is not overvalued.
June 04, 2024
Via
Chartmill
While growth is established for NASDAQ:HALO, the stock's valuation remains reasonable.
May 14, 2024
Via
Chartmill
Halozyme Therapeutics Scores RS Rating Jump To 91
June 07, 2024
Via
Investor's Business Daily
This Exxon Mobil Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday
June 07, 2024
Via
Benzinga
Why G-III Apparel Shares Are Trading Lower By 13%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
June 06, 2024
Via
Benzinga
Expert Ratings For Halozyme Therapeutics
May 07, 2024
Via
Benzinga
Exploring the Growth Potential of NASDAQ:HALO as It Nears a Breakout.
April 30, 2024
Via
Chartmill
Halozyme Therapeutics +13% On Thursday: What's Going On?
June 06, 2024
Via
Benzinga
Topics
Intellectual Property
Exposures
Intellectual Property
J.M. SmuckerPosts Upbeat Earnings, Joins Toro Company, United Natural Foods, Semtech And Other Big Stocks Moving Higher On Thursday
June 06, 2024
Via
Benzinga
A Glimpse Into The Expert Outlook On Halozyme Therapeutics Through 8 Analysts
June 04, 2024
Via
Benzinga
NASDAQ:HALO is probably undervalued for the fundamentals it is displaying.
May 29, 2024
Via
Chartmill
Halozyme Therapeutics Stock Earns IBD Stock Rating Upgrade, Hitting 80-Plus RS Rating
May 16, 2024
Via
Investor's Business Daily
Catalyst Pharmaceuticals Stock Clears Technical Benchmark With 83 RS Rating
May 14, 2024
Via
Investor's Business Daily
The 3 Best Biotech Stocks to Buy in May 2024
May 09, 2024
Via
InvestorPlace
When you look at NASDAQ:HALO, it's hard to ignore the strong fundamentals, especially considering its likely undervaluation.
May 08, 2024
Via
Chartmill
HALO Stock Earnings: Halozyme Therapeutics Beats EPS, Misses Revenue for Q1 2024
May 07, 2024
Via
InvestorPlace
PTC Therapeutics Stock Sees IBD RS Rating Climb To 72
May 01, 2024
Via
Investor's Business Daily
Sarepta Therapeutics Stock Shows Improved Technical Strength
April 29, 2024
Via
Investor's Business Daily
3 Biotech Stocks That Could Be Multibaggers in the Making: April Edition
April 25, 2024
Via
InvestorPlace
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.